Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2002

View Archived Issues

Epicyte partners with aaiPharma to develop topical monoclonal antibody

MalariVax phase I commences at U.S. and U.K. sites

Discovery of back-up HNE inhibitors detailed by GSK

E-selectin vaccine prevents stroke in rat model

Roche designs neuroprotective agents with reduced side effect liability

Sustained beneficial effects reported for tadalafil in men with ED

Research findings support use of KRP-197 for overactive bladder

Micrologix acquires antiviral product and technology portfolio

Incenta presents new cruzipain inhibitors for use in Chagas' disease

AWD-12-281 compares favorably with other PDE4 inhibitors in terms of safety margin

Novel IL-8 antagonists and their use in psoriasis, arthritis, etc.

Merck and Isis researchers identify new HCV NS5B polymerase inhibitors

New alpha4beta1/alpha4beta7 integrin antagonists identified at Almirall Prodesfarma

Coagulation factor inhibitors covered by Merck patent

Lipoxin A4 produced in human bronchial epithelium, exerts antiinflammatory effects

Phase III Tarceva trial in NSCLC completes enrollment

Pharmexa reacquires AutoVac(TM) TNF-alpha pharmaccine

European approval for Fosrenol delayed

SuperGen's decitabine awarded orphan drug status for sickle cell anemia

Tularik advances T-487 into phase I trials

Xigris evaluated in severe sepsis patients at low risk of death

Provigil improves ADHD symptoms in children

Therion licenses rights to ICAM-1 from Boehringer Ingelheim

Debiopharm and Biolex form recombinant human therapeutic protein collaboration

Dyax schedules second phase II trial of DX-88 in hereditary angioedema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...